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Introduction
Testosterone is a hormone that, in males, was originally 
associated primarily with sexual functions (e.g. libido, 
potency, and semen production). Nevertheless, it also 
has many additional metabolic actions. Firstly, it in-
creases the synthesis of erythropoietin and boosts the 
tissue iron bioavailability. Testosterone also contributes 
to osteogenesis and stimulates muscle growth. 
Testosterone deficiency may cause several com-
plications. The most frequent is sexual dysfunction. 
Hypogonadism is associated with decreased libido, 
and impaired sexual function in men (ejaculatory and 
erectile dysfunction) [1, 2]. In a study by Araujo et al. 
it was reported that in men from the general popula-
tion with TT < 300 ng/dL and FT < 5 ng/dL, low libido 
and erectile dysfunction occurred in 26% and 36%, 
respectively [2]. In men, testosterone deficiency may 
be linked to the development of osteoporosis, anaemia, 
and reduced muscle mass (sarcopaenia). Also, in these 
patients, abnormalities in body composition occur: the 
fat volume increases and the muscle mass is lowered 
[1, 3]. It has been observed that testosterone deficiency 
is associated with increased cardiovascular risk in the 
general male population [1]. Moreover, results of recent 
studies show that testosterone deficiency is linked to 
being frail or becoming frail in one year, as well as physi-
cal dysfunction in men on chronic haemodialysis [4].
In the general population testosterone deficiency is 
usually associated with aging and is observed in 6–10% 
of men (40–75 years old) [4]. Many chronic diseases, 
e.g. diabetes mellitus type 2, obesity, metabolic syn-
drome, depression, rheumatoid flares, hypertension, 
and chronic kidney disease, result in decreased serum 
testosterone concentration [2, 5, 6, 7]. Moreover, result of 
a recent study documented that low serum testosterone 
concentration is a risk factor of CKD progression in the 
male population [8].
In men with CKD the serum testosterone concentra-
tion decreases with the deterioration of kidney function 
and is the lowest in patients receiving renal replacement 
therapy. In the study by Carrero et al. a 44% prevalence 
of total testosterone (TT) deficiency (serum TT concen-
tration < 2.9 ng/mL) among haemodialysis patients 
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Bensheim, Germany; IL-6 [hs] — R&D Systems, Abbinton, United 
Kingdom). Serum TT and FT concentrations were assessed with 
radioimmunoassay and SHBG with an IRMA technique (DIAsource 
Immunoassays, Nivelles, Belgium).
Patients were divided into three age subgroups: 19–39 years (18 
patients), 40–59 years (34 patients), and ≥ 60 years (27 patients). 
TT insufficiency and deficiency were diagnosed, according to 
the recommendation of the Endocrine Society [14], when serum 
TT concentration was below 4.0 and 2.9 ng/mL, respectively. FT 
deficiency was diagnosed in patients with serum FT concentra-
tion below 8.9, 6.6, and 4.9 pg/mL in the abovementioned age 
subgroups, respectively.
Statistical analyses were done using the Statistica 10.0 PL software 
(StatSoft Polska, Cracow, Poland). ANOVA was used to assess differ-
ences in serum testosterone concentration between age subgroups, 
and chi-square to assess differences in the frequency of testosterone 
deficiency and insufficiency incidence. Correlation coefficients 
were calculated using Spearman’s rank correlation. To reduce the 
possibility of an incidental nature of the obtained significant cor-
relations, the multiple regression models were calculated with the 
serum FT and TT concentrations as dependent variables and factors 
that reached significance in correlation analyses as independent 
variables (i.e serum CRP and IL-6 concentrations and the patients’ 
age). The results are presented as means with 95% confidence in-
terval (CI); differences were considered significant when p < 0.05.
Results
The mean serum TT concentration in the whole study 
group was 4.92 ng/mL. In the patients’ age subgroups 
analyses a significantly lower serum TT concentra-
tion was found in the oldest patients compared to the 
youngest group (Tab. 1).
The mean serum FT concentration in the whole 
study group was 6.64 pg/mL. In the patients’ age sub-
group analyses a significantly lower serum FT concen-
tration was also found in the oldest patients compared 
to the youngest group (Tab. 1). Serum concentrations 
of IL-6, CRP, and SHBG in the studied group are pre-
sented in Table 2.
In the whole group TT insufficiency (2.9–4.0 ng/mL) 
and deficiency (< 2.9 ng/mL) were found in 25% and 
15% patients, respectively (cumulatively 40% of patients 
had abnormal serum TT concentration). Abnormal 
serum TT concentration (both TT insufficiency and 
deficiency) was found in 24% of patients in the youngest 
age subgroup, in 42% of patients in the intermediate age 
subgroup, and in 46% of patients in the oldest age sub-
group (the differences were not significant statistically: 
c2 p = 0.15). TT deficiency was found in 18% of patients 
was observed, whereas TT insufficiency (serum TT 
concentration 2.9–4.0 ng/mL) was observed in 33% of 
patients. Only 23% of haemodialysis men had normal 
serum TT concentration (> 4.04 ng/mL) [3]. 
The low serum testosterone concentration in hae-
modialysis men may be caused by dysfunction of the 
hypothalamic–pituitary–testicular axis: impaired GnRH 
secretion, luteinizing hormone (LH) and follicle stimu-
lating hormone (FSH) accumulation, increased serum 
prolactin (PRL), and reduction of 5-a reductase activity. 
The aforementioned abnormalities lead to an inap-
propriate signalling for the Leydig cells to produce 
testosterone [9–12]. What is more, it has been shown 
that in haemodialysis men with secondary hyperpara-
thyroidism, treatment with cinacalcet may contribute 
to the decrease of serum TT and FT concentration [13]. 
The results of observational studies suggest that low 
serum testosterone concentration is correlated with 
higher mortality in haemodialysis patients [12].
In humans two testosterone fractions can be dis-
tinguished. The bioavailable, bioactive testosterone 
fraction, which contains free testosterone (FT), and 
testosterone bound to albumin. In contrast, testosterone 
bound with sex hormone-binding globulin (SHBG) is 
not active. The total amount of serum testosterone is 
described as the serum total testosterone concentration 
(TT) [1].
Taking into consideration , the severe consequences 
of testosterone deficiency, the frequent occurrence of 
endocrine disturbances in haemodialysis CKD patients, 
and the high mortality in this group of patients, as 
presented above, it seemed reasonable to investigate 
the prevalence of TT and FT deficiency in CKD men 
on maintenance haemodialysis.
Material and methods
Seventy-nine adult, haemodialysis male CKD patients were en-
rolled in this study. Tye mean age of patients was 54.0 (51.5–57.5) 
years. In all patients, serum TT, FT, SHBG, interleukin 6 (IL-6), C-
reactive protein (CRP), and albumin concentrations were assessed. 
Blood samples were collected before a haemodialysis session in 
the middle of the week, two days after preceding dialysis session. 
Blood samples after collection were centrifuged and then frozen 
at –70°C until assay was done. Serum albumin, CRP, and IL-6 
concentrations were assessed with an ELISA kit (albumin — As-
saypro LLC, St. Charles, MO, USA; CRP — Immundiagnostik AG, 








TT concentration [ng/mL] 5.9 (4.6–7.1) 4.8 (3.9–5.4) 4.6 (3.9–5.3)*
FT concentration [pg/mL] 7.9 (5.2–10.1) 6.1 (5.1–7.2) 6.0 (5.0–7.1)*
*p < 0.05 vs. patients in the age group 18–39 years
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in the first subgroup, 16% in the second subgroup, and 
12% in the third subgroup (the differences were also 
not significant statistically: chi2 p = 0.74). 
FT deficiency was found in 50% of patients. In the 
patients age subgroups FT deficiency was found in 78%, 
56%, and 26%, respectively. Testosterone insufficiency 
was significantly more frequent in young patients (chi2 
p = 0.01)
A significant negative correlation was found be-
tween both serum TT and FT concentrations and age 
(r = –0.23, and r = –0.27, p < 0.05) (Fig. 1, 2), respective-
ly. Moreover, significant inverse correlations were found 
between both TT and FT and IL-6 (r = –0.43, p < 0.05 
and r = –0.29, p < 0.05) (Fig. 3, 4), respectively. A border-
line significance correlation was found between serum 
TT and urea concentrations (r = 0.21; p = 0.09). There 
were no significant correlations between serum TT and 
FT concentration and serum CRP, PTH, albumin, and 
SHBG concentration, nor the patients’ age. 
In the multiple regression analysis, the serum FT 
concentration was inversely explained by the serum 
IL-6 concentration (rpartial = –0.27; p = 0.01) and patients’ 
age (rpartial = –0.25; p = 0.03). The serum TT concentra-
tion was inversely explained by the serum IL-6 concen-
tration (rpartial = 20.43; p=0.002). 
Discussion
In the current study, we have found a high prevalence 
of testosterone deficiency in patients on maintenance 
haemodialysis. This is in agreement with the results of 
previous studies in which the percentage of men with 
hypogonadism reached as much as 57% in men with 
CKD stage 5 [5, 15, 16].
In the current study we have found in that in pa-
tients on maintenance haemodialysis both serum TT 
and FT concentrations decrease with age. Other stud-
ies concerning this issue yielded similar results [5, 15, 
16]. It is not yet clear why such a high percentage of 
CKD patients develop hypogonadism. Most likely the 
disturbances in the hypothalamic-pituitary-gonadal 
axis are the most important contributing component 
[17, 18]. Also, the direct damage to the Leydig cells 
caused by uraemia [18, 19] and the impact of different 
medications [13] must be taken into consideration as 
factors causing low testosterone concentrations in men 
with CKD. A surprising finding of the current study 
is that testosterone deficiency is more frequent in the 
group of younger patients than in the elderly. This 
Table 2. Serum interleukin 6 (IL-6), C-reactive protein (CRP), 
and sex hormones binding globulin (SHBG) concentrations 
in maintenance haemodialysis males
Mean 95% CI
IL-6 [pg/mL] 7.44 6.33–8.57
CRP [mg/L] 11.09 9.71–12.47
SHBG [mmol/L] 28.90 25.44–32.35
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may be explained by the different cut-off points for the 
diagnosis of FT deficiency in different age groups. It is 
important to stress that there are no universal normal 
values of FT plasma concentration in the endocrinologi-
cal guidelines. The clinical significance of this finding 
needs further elucidation, but there are more and 
more data available suggesting that low testosterone 
plasma concentration levels may be one of the causes 
of increased mortality in men with CKD and treated 











































































Figure 2. Negative correlation between serum free testosterone and age
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The mean serum concentration of serum SHBG in 
our study group (Tab. 2) was similar to the concentra-
tions obtained by Hylander et al. [21], who analysed 
men with CKD stages 1–5, suggesting that SHBG is not 
related to the magnitude of kidney damage nor the use 
of renal replacement therapy. 
Moreover, in the current study, we have found 
a significant inverse correlation between the marker 
of inflammatory status (serum IL-6 concentration) and 
serum concentration of both FT and TT. Taking into 
consideration the cross-sectional character of the cur-
rent study, we have built multiple regression models 
to assess a more causal character of the observed rela-
tions. The TT concentration was inversely explained by 
serum IL-6 concentrations, and FT levels by both IL-6 
concentration and age. This finding is, in general, in 
concordance with the results of previous studies [5, 15, 
16]; however, we have found only the relation between 
IL-6 and TT of FT, while Carrero et al. observed strong 
correlation between serum testosterone concentration 
and another inflammatory marker – C-reactive protein. 
The differences may be explained by different tests used 
for the assessment, and the fact that the mean CRP 
values in both studies were not very high — 11 mg/L in 
our study and 6–16 mg/L (depending on the group) in 
the study by Carrero et al. This falls into the diagnosis 
of microinflammation rather than an overt inflamma-
tory process. There are only a few studies published 
concerning the interrelation of microinflammation and 
testosterone plasma concentration in men. It was shown 
that in diabetic patients [22] testosterone concentration 
is also inversely related to the serum CRP and IL-6 con-
centrations; however, testosterone replacement therapy 
did not have an impact on the concentration of these 
cytokines. On the other hand, the results of a recent 
study by Dudek et al. [23] showed a significant decrease 
of serum CRP concentration in men with age-related 
hypogonadism treated with testosterone replacement 
therapy compared to placebo. Results of experimental 
studies suggest that testosterone may attenuate the 
secretion of inflammatory cytokines and thus protect 
the kidney against the ischemia-reperfusion damage 
[24]. This might explain the faster CKD progression in 
men with low serum testosterone concentration ob-
served by Amri et al. [12]. It seems that testosterone has 
anti-inflammatory properties, as recently described by 
Bianchi [25]. It should be also mentioned that in some 
preliminary clinical studies it was shown that ESA treat-
ment increased plasma testosterone concentrations in 
haemodialysis patients [26, 27].
Our study has some limitations. The most impor-
tant is the retrospective, cross-sectional nature of our 
analyses, which precludes drawing firm conclusions of 
causality of the obtained results. The studied population 
was also not very large.
Conclusions
In the current study a significant decrease of serum TT 
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ertheless, testosterone deficiency was more frequently 
diagnosed in younger patients. Moreover, hypogonad-
ism seems to be related to the inflammatory status of 
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